This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Report From the Panel on Photoreceptor/Retinal Pigment Epithelium

Dean Bok, PhD; Gregory S. Hageman, PhD; Roy H. Steinberg, MD, PhD; Photoreceptor/Retinal Pigment Epithelium Panel

Arch Ophthalmol. 1993;111(4):463-471.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

A principal goal of research on the retina is to prevent blindness by devising new therapies for diseases that cause photoreceptor dysfunction or loss. These diseases affect the photoreceptor/retinal pigment epithelium (RPE) region (from the choriocapillaris to the outer plexiform layer) and ultimately injure or destroy the rods and cones. The pathophysiological mechanism may be a direct attack on the photoreceptor, or it may involve the cellular and extracellular environment that supports photoreceptor viability. Recent advances in basic science and in clinical medicine make it possible now to conceive of new therapies that would prevent injury to photoreceptor cells, or repair already injured cells, or even replace injured or dead cells, such as the RPE, or the photoreceptors.

There is, of course, a precedent in ophthalmology for therapies that provide partial repair of the damaged retina. Two prime examples are retinal reattachment surgery for retinal detachment and the use of . . . [Full Text PDF of this Article]

Author Affiliations
From the Jules Stein Eye Institute and Department of Anatomy and Cell Biology, UCLA, Los Angeles, Calif (Dr Bok); the Bethesda (Md) Eye Institute and Department of Ophthalmology, St Louis (Mo) University School of Medicine (Dr Hageman); and the Departments of Physiology and Ophthalmology, University of California San Francisco, School of Medicine (Dr Steinberg). Dr Steinberg is a consultant for Regeneron Pharmaceuticals Inc, Tarrytown, NY. For a list of the members of the Photoreceptor/Retinal Pigment Epithelium Panel, see end of this article.

Footnotes
Accepted for publication November 20, 1992.

Reprint requests to Department of Ophthalmology, University of California School of Medicine, San Francisco, CA 94143-0730 (Dr Steinberg).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?